Ani Pharmaceuticals (ANIP) Current Assets (2010 - 2026)

Ani Pharmaceuticals has disclosed Current Assets across 17 years of filings, most recently posting $747.1 million for Q1 2026.

• Current Assets for Q1 2026 came in at $747.1 million, up 39.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $747.1 million (up 39.31% YoY), and the FY2025 annual result was $753.1 million, up 42.51% from the prior year.
• Current Assets came in at $747.1 million for Q1 2026 at Ani Pharmaceuticals, down from $753.1 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $753.1 million in Q4 2025 to a low of $301.4 million in Q1 2022.
• The 5-year median for Current Assets is $521.3 million (2024), against an average of $506.0 million.
• Across the five-year window, Current Assets surged 68.09% in 2022 and dropped 0.79% in 2025, its largest moves.
• Ani Pharmaceuticals' Current Assets stood at $344.3 million in 2022, then surged by 50.99% to $519.8 million in 2023, then gained by 1.66% to $528.5 million in 2024, then surged by 42.51% to $753.1 million in 2025, then retreated by 0.8% to $747.1 million in 2026.
• The last three Current Assets figures came in at $747.1 million (Q1 2026), $753.1 million (Q4 2025), and $698.4 million (Q3 2025), per Business Quant data.